As Trade Tensions Rise, Reckitt Strengthens Local Supply Chains in China and the United States

Reckitt is increasing local production in China and the United States to reduce its reliance on imports and protect its supply chain from potential trade conflicts. The group invested $190 million in North Carolina to build a plant to produce Mucinex; and invested 300 million yuan (40.9 million US dollars) in Shanghai to build a research and development center.

The North Carolina plant will be operational in 2027 and will reduce US imports to 25% of Reckitt's local sales by producing Mucinex tablets and liquids domestically.

In China, Reckitt is expanding its Taicang plant to produce contraceptive products from 2026, and its new Shanghai R&D center will focus on developing products suitable for the local market.

As the United States considers protectionist policies and imposes tariffs of up to 60% on Chinese imports, Reckitt's strategy aims to reduce its reliance on single sourcing while enhancing manufacturing flexibility.

Currently, 80% of Reckitt's products sold in China are locally produced, and the company is well positioned to meet consumer demand despite trade uncertainties.

Reckitt's proactive investment reflects its strategic focus on strengthening its supply chain to address geopolitical challenges.